Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT07474792 · Plaque Psoriasis
NCT06857942 · Psoriasis, Overweight or Obesity
NCT06979453 · Plaque Psoriasis
NCT07449234 · Psoriasis
NCT07471048 · Psoriasis
EP Pharmaline
Tosima-ku, Tokyo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions